# LACunar Intervention (LACI-2) Trial-2

Study · id `cardio:ct-nct03451591` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03451591](<https://clinicaltrials.gov/study/NCT03451591>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03451591

Browse, organ or system: Blood vessels; Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 363 participants.

## Technical summary

Registry record NCT03451591. Randomized; single masking; primary purpose prevention. Start 2018-01-08 (actual); primary completion 2022-05-31 (actual). Results posted on 2024-11-12.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 2/3
- Enrolled: 363 participants (enrolled count; ClinicalTrials.gov record NCT03451591, source copy `cardio:ctgov-nct03451591-2024-11-12`, retrieved 2026-10-26)
- Started: 2018-01-08 (actual) (ClinicalTrials.gov record NCT03451591, source copy `cardio:ctgov-nct03451591-2024-11-12`, retrieved 2026-10-26)
- Primary completion: 2022-05-31 (actual) (ClinicalTrials.gov record NCT03451591, source copy `cardio:ctgov-nct03451591-2024-11-12`, retrieved 2026-10-26)
- Completion: 2022-08-11 (actual) (ClinicalTrials.gov record NCT03451591, source copy `cardio:ctgov-nct03451591-2024-11-12`, retrieved 2026-10-26)
- Results first posted: 2024-11-12 (ClinicalTrials.gov record NCT03451591, source copy `cardio:ctgov-nct03451591-2024-11-12`, retrieved 2026-10-26)
- Countries: United Kingdom (ClinicalTrials.gov record NCT03451591, source copy `cardio:ctgov-nct03451591-2024-11-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03451591-2024-11-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: LACunar Intervention (LACI-2) Trial-2
- Acronym: LACI-2
- Condition: Cerebral Small Vessel Diseases
- Condition: Stroke, Lacunar
- Intervention (Drug): Isosorbide Mononitrate XL (ISMN)
- Intervention (Drug): Cilostazol
- Intervention (Drug): ISMN XL and Cilostazol
- Intervention (Other): Neither ISMN nor cilostazol
- Lead sponsor: University of Edinburgh
- Lead sponsor class: OTHER
- Collaborator: British Heart Foundation
- Collaborator class: OTHER
- Collaborator: University of Nottingham
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Cerebral small vessel disease (`cardio:cerebral-small-vessel-disease`)
- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: University of Edinburgh (`cardio:org-university-of-edinburgh`)
- Registry lists this organization as a collaborator: British Heart Foundation (`cardio:org-british-heart-foundation`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Isosorbide Mononitrate and Cilostazol Treatment in Patients With Symptomatic Cerebral Small Vessel Disease: The Lacunar Intervention Trial-2 (LACI-2) Randomized Clinical Trial (`cardio:pubmed-37222252`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 8f599f38af40114559d9f5125511919155774dcaa2c8fcb1c7b5d108e1387585
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
